Trinity Biotech director reports ADS option holdings
Trinity Biotech plc director John Gillard filed an amended initial insider report detailing his existing holdings in American Depositary Share (ADS) options and ADSs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3/A
Rhea-AI Filing Summary
Trinity Biotech plc director John Gillard filed an amended initial insider report detailing his existing holdings in American Depositary Share (ADS) options and ADSs. The filing shows multiple option grants, including ADS options over 40,000 shares at an exercise price of $5.70 expiring on December 19, 2029, and ADS options over 43,750 shares at an exercise price of $2.40 expiring on December 11, 2030. It also notes ADS options over 7,500 shares at an exercise price of $13.45 expiring on October 23, 2027, along with direct ownership of 10,000 ADSs. The report records holdings only and does not show any new purchases or sales.
Insider Trade Summary
31 transactions reported
Mixed
31 txns
Insider
Gillard John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS OPTIONS | -- | -- | -- |
| holding | ADS | -- | -- | -- |
Holdings After Transaction:
ADS OPTIONS — 970,837 contracts (Direct);
ADS — 10,000 shares (Direct)
Footnotes (1)
- F1. See Exhibit 99.1 for additional holdings details.
Key Figures
Direct ADS holdings: 10,000 ADSs
ADS options at $13.45: 7,500 underlying shares
ADS options at $5.70: 40,000 underlying shares
+3 more
6 metrics
Direct ADS holdings
10,000 ADSs
Direct ownership reported as of March 18, 2026
ADS options at $13.45
7,500 underlying shares
Exercise price $13.45; expiration October 23, 2027
ADS options at $5.70
40,000 underlying shares
Exercise price $5.70; expiration December 19, 2029
ADS options at $5.45
35,000 underlying shares
Exercise price $5.45; expiration March 25, 2029
ADS options at $2.40 (Dec 11 2030)
43,750 underlying shares
Exercise price $2.40; expiration December 11, 2030
ADS options at $2.40 (Dec 19 2030)
29,167 underlying shares
Exercise price $2.40; expiration December 19, 2030
Key Terms
ADS OPTIONS, Form 3/A, exercise price, derivative securities
4 terms
ADS OPTIONS financial
"Security title reported as ADS OPTIONS with matching underlying ADS OPTIONS."
Form 3/A regulatory
"Amended Form 3/A filing updates initial insider holdings disclosure."
An amended Form 3 (Form 3/A) is a corrected or updated disclosure filed with regulators that revises an insider’s initial report of their ownership in a public company — typically for officers, directors or large shareholders. Investors use it like a corrected inventory list: it clarifies who owns how many shares and whether earlier reports had errors, helping assess insider confidence, possible conflicts and the accuracy of ownership records that can affect stock valuation and trust.
exercise price financial
"Each ADS option grant lists a specific exercise price such as $2.40 or $5.70."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"ADS OPTIONS are disclosed as derivative securities representing rights to acquire ADSs."
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Trinity Biotech (TRIB) director John Gillard report in this Form 3/A?
John Gillard reports his existing holdings of ADS options and ADSs in an amended initial insider filing. The report lists multiple option grants with specific exercise prices and expirations, plus 10,000 ADSs held directly, and does not show any new purchases or sales.
How many Trinity Biotech ADS options at $5.70 does John Gillard hold?
The filing lists ADS options over 40,000 underlying shares at a $5.70 exercise price expiring on December 19, 2029. These options are reported as derivative holdings, indicating a right to acquire ADSs at that price before expiration, not a completed purchase or sale.
What low-price ADS option positions does John Gillard disclose in TRIB?
Gillard discloses ADS options over 43,750 underlying shares at a $2.40 exercise price expiring December 11, 2030, and additional 29,167-share tranches at the same $2.40 price expiring December 19, 2030. These entries outline derivative positions, not current ADS ownership.
Does this Trinity Biotech Form 3/A show any insider buying or selling?
No. The filing categorizes all entries as holdings with unknown transaction codes and shows zero buy or sell counts in the transaction summary. It updates John Gillard’s reported ADS option and ADS positions without indicating new market transactions or changes in his stake.
What direct ADS ownership does John Gillard report in Trinity Biotech (TRIB)?
The filing shows John Gillard directly holding 10,000 Trinity Biotech ADSs. This position is separate from his ADS option grants and reflects current share ownership rather than derivative rights, as recorded on the same March 18, 2026 reference date for his holdings.
What are the key expiration dates for John Gillard’s Trinity Biotech ADS options?
Key expirations include October 23, 2027 for options at $13.45, March 25, 2029 for options at $5.45, December 19, 2029 for options at $5.70, and December 11 and 19, 2030 for several $2.40 option tranches, defining the time window to exercise these rights.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates